Trovafloxacin

Drugs

Volumn 54, Issue 3, 1997, Pages 435-445

  Haria, Malini ^a   Lamb, Harnet M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; BACTEROIDES; CHLAMYDIA TRACHOMATIS; CLOSTRIDIUM; DIARRHEA; ENTEROBACTERIACEAE; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HEADACHE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; MYCOPLASMA; NAUSEA; NEISSERIA GONORRHOEAE; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION; VAGINITIS; VERTIGO; VOMITING;

BACTERIA (MICROORGANISMS); BACTEROIDES; CHLAMYDIA TRACHOMATIS; CLOSTRIDIUM; ENTEROBACTERIACEAE; HAEMOPHILUS INFLUENZAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; MYCOPLASMA; MYCOPLASMATALES; NEGIBACTERIA; NEISSERIA GONORRHOEAE; POSIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCI; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0030800464     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754030-00006     Document Type: Review

References (48)

1. Brighty KE, Gootz TD, Girard A, et al. Prodrugs of CP-99,219 for intravenous administration; synthesis and evaluation resulting in identification of CP-116,517 [abstract no. 730]. 7th European Congress or Clinical Microbiology and Infectious Diseases; 1995 Mar 26-30: Vienna, 141
2. Gootz TD, Brighty KE, Anderson MR, et al. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial. Diagn Microbiol Infect Dis 1994 Aug: 19: 235-43
3. Neu HC, Chin N-X. In vitro activity of the new fluoroquinolone CP-99,219, Antimicrob Agents die-mother 1994 Nov: 38: 2615-22
4. Verbist L, Verhaegen J. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates. Fur J Clin Microbiol Infect Dis 1996 Aug; 15: 683-5
5. Sefton AM, Maskell JP, Seymour AC, et al. Comparative invitro activity of CP-99219. a new quinolone. against respiratory pathogens. J Antimicrob Chemother 1996 Apr; 37: 803-8
6. van Rijsoort-Vos JH, Stolz E, Verbrugh HA, et al. In-vitro activity of a new quinolone (CP-99,219) compared with ciprofloxacin, pefloxacin, azithromycin and penicillin against Neisseria gonorrhoeae. J Antimicrob Chemother 1995; 36: 215-8
7. Knapp JS, Neal SW, Parekh MC, et al. In vitro activity of a new fluoroquinolonc, CP-99,219, against strains of Neisseria gonorrhoeae. Antimicrob Agents Chemother 1995 Apr: 39: 987-9
8. Jones RB, Van Der Pol B, Johnson RB. Susceptibility of Chlamydia trachomatis to trovafloxacin. J Antimicrob Chemother 1997 Jun; 39 Suppl. B: 63-5
9. Roblin PM, Hammerschlag MR. In vitro activity of trovafloxacin against Chlamydia pneumoniae [abstract no. 2244], 20th International Congress of Chemotherapy: 1997 Jun 29-Jul 3; Sydney, 28
10. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma pneumonia, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob Agents Chemother 1996 Apr: 40: 1048-9
11. Edelstein PH, Edelstein MAC, Ren J, et al. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1996 Feb; 40 (2): 314-9
12. Girard AE, Cimochowski CR, Girard D, et al. In vitro and in vivo activities of CP-99,219 against Helicobacter [abstract no. F24]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy 1994; 1994 Oct 4-7; Orlando, 55
13. Eliopoulos GM, Klimm K, Eliopoulos CT. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrob Agents Chemother 1993 Feb: 37: 366-70
14. Klugman K, Wasas A. In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae. J Antimicrob Chemother 1995 Nov; 36: 873-4
15. Gootz TD, Zaniewski R, Haskell S, et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother 1996 Dec: 40: 2691-7
16. Pankuch GA, Jacobs MR, Appelhaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995 Jan: 35: 230-2
17. Thomson KS, Chartrand SA, Sanders CS, et al. Trovafloxacin, a new fluoroquinolonc with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41: 478-80
18. Urbásková P, Trupl J, Hupková H, et al. In vitro susceptibility of pncumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia. Eur J Clin Microbiol Infect Dis 1996; 15: 686-8
19. Cormican MG, Jones RN. In-vitro activity of trovafloxacin (CP99-219) tested by two methods against 150 vuncomycinresistant enterococcal isolates. J Antimicrob Chemother 1996 Apr; 37: 847-9
20. Freeman C, Robinson A, Cooper B, et al. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagn Microbiol Infect Dis 1995 Jan; 21: 47-50
21. Wexler HM, Molitoris E, Molitoris D, et al. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother 1996 Sep; 40: 2232-5
22. Girard AE, Girard D, Gootz TD, et al. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against Gram-positive pathogens, Streptococcus pneumoniac, and Bacteroides fragilis. Antimicrob Agents Chemother 1995 Oct; 39: 2210-6
23. Kim YS, Liu Q, Chow LL, et al. Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptoccus pneumoniae. Antimicrob Agents Chemother 1997; 41 (5): 1186-9
24. París MM, Hickey SM, Trujillo M. Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1995 Jun; 39: 1243-6
25. Onderdonk AB. Efficacy of trovafloxacin (CP-99,219), a new fluoroquinolone, in an animal model of intraabdominal sepsis. Infect Dis Clin Pract 1996 Jun-Jul; 5 Suppl. 3: 117-9
26. Thadepalli H, Reddy U, Chuah SK, et al. Effect of new quinolone, CP-99,219-27, in curing intraabdominal abscesses in rats. Infect Dis Clin Pract 1996 Jun-Jul; 5 Suppl. 3: 120-1
27. Andrews JM, Honcybourne D, Brenwald NP, et al. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibreoptic bronchoscopy. J Antimicrob Chemother 1997 Jun; 39: 797-802
28. Teng R, Harris SC, Nix DE, et al. Pharmucokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother 1995 Aug; 36: 385-94
29. Dalvie DK, Khosla N, Vincent J. Excretion and metabolism of trovafloxacin in humans. Drug Metab Dispos 1997; 25 (4): 423-7
30. Wise R, Mortiboy D, Child J. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99.219). Antimicrob Agents Chemother 1996 Jan; 40: 47-9
31. Teng R. Dogolo LC, Willavizc SA, et al. Effect of age and gender on the pharmacokinetics of CP-99,219, a new quinolone antibiotic, in healthy volunteers [abstract no. F238]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, 154
32. Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chcmother 1996 May; 37: 955-63
33. Vincent J, Venitz J, Teng R, et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J Antimicrob Chemother 1997 Jun; 39 Suppl. B: 75-80
34. Cutler NR, Vincent J, Jhee SS, et al. Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin. Antimicrob Agents Chemother 1997 Jun; 41 (6): 1298-300
35. Teng R, Dogolo LC, Willavize SA, et al. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother 1997; 39 Suppl. B: 93-7
36. Teng R, Dogolo LC, Willavize S, et al. Effect of sucralfate, calcium carbonate and ferrous sulphate on the bioavailability of trovafloxacin [abstract no. 71.007]. 7th International Congress for Infectious Diseases; 1996 Jun 10-13; Hong Kong, 186
37. Teng R, Dogolo LC, Willavize SA, et al. Oral bioavailability of trovafloxacin with and without food in healthy volunteers. J Antimicrob Chemother 1997 Jun; 39 Suppl. B: 87-92
38. Vincent J, Teng R, Dogolo LC, et al. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. J Antimicrob Chemother 1997 Jun; 39 Suppl. B: 81-6
39. Patterson BE, Pukins L, Oliver SJ, et al. An open, placebo-controlled, two-way crossover study to investigate the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin [abstract no. 71.019]. 7th International Congress for Infectious Diseases; 1996 Jun 10-13; Hong Kong, 188
40. Teng R, Apseloff G, Vincent J, et al. Effect of trovafloxacin (CP-99,219) on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects [abstract no. A2]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans, 1
41. Patterson BE, Kleinermans D, Brown SJ, et al. Effects of orally administered trovafloxacin on the steady-state pharmacokinetics of digoxin: results of a double-blind, placebo-control- led, parallel-group study [abstract no. 70.022]. 7th International Congress for Infectious Diseases: 1996 Jun 10-13; Hong Kong
42. Fiddes R, Syndor A, Johnson P, et al. The efficacy and safety of trovafloxacin in the treatment of acute bacterial sinusitis [abstract no. 2263]. 20th International Congress of Chemotherapy: 1997 Jun 29-Jul 3; Sydney, 32
43. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997 Jun; 39 Suppl. B: 1-14
44. Anonymous. Pfizer highlighting ziprasidone lower weight gain in schizophrenics compared to Lilly Zyprexa; trovafloxacin NDA filing for 12 indications set for December. FDC Pink 1996 November 4: 12
45. Hook III EW, Pinson GB, Blalock CJ. Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea. Antimicrob Agents Chemother 1996 Jul; 40: 1720-1
46. Martin DH, Jones RB, Johnson RB. A phase 11 study of CP-99,219-27 for the treatment of Chlamydia trachomatis infections [abstract no. LM33]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco, 332
47. Pfizer Inc. Data on file
48. Ferguson J, Patterson BE, Purkins L. et al. An open, observer-blinded, placebo-controlled, randomized, parallel-group study to investigate the phototoxic potential of trovafloxacin, ciprofloxacin and lomefloxacin [abstract no. A15]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 15-18 Sep; New Orleans